Unmet needs for patients with seborrheic dermatitis.

Seborrheic dermatitis (SD) is a common skin disease with signs and symptoms that may vary by skin color, associated medical conditions, environmental factors, and vehicle preference. Diagnosis of SD is based on presence of flaky, "greasy" patches, and/or thin plaques accompanied by erythema of the scalp, face, ears, chest, and groin and is associated with pruritus in many patients. The presentation may vary in different skin types and hyper- or hypopigmentation may occur, with or without erythema and minimal or no scaling. While the pathogenesis is not certain, 3 key factors generally agreed upon include lipid secretion by sebaceous glands, Malassezia spp. colonization, and some form of immunologic dysregulation that predisposes the patient to SD. Treatment involves reducing proliferation of, and inflammatory response to, Malassezia spp. Topical therapies, including antifungal agents and low potency corticosteroids, are the mainstay of treatment but may be limited by efficacy and side effects. Few novel treatments for SD are currently being studied; however, clinical trials assessing the use of topical phosphodiesterase-4 inhibitors have been completed. Improving outcomes in SD requires recognizing patient-specific manifestations/locations of the disease, including increased awareness of how it affects people of all skin types.

Informations de copyright

Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest Dr Jackson received research, honoraria, consulting, and/or other support from the following companies over the last 12 months: AbbVie, Arcutis, BMS, Dermavant, Evommune, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB. Dr Alexis received grants (funds to institution) from Leo, Novartis, Almirall, Bristol-Myers-Squibb, Amgen, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis, Dermavant; Advisory board/Consulting: Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Valeant, L'Oreal, BMS, Bausch Health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, AbbVie, Sol-Gel , Amgen, VisualDx, Eli Lilly, Swiss American; Speaker: Regeneron, Sanofi-Genzyme, Pfizer, and BMS. Dr Zirwas received research, honoraria, consulting, and/or other support from the following companies: AbbVie, All Free Clear/Sun, Anaptys Bio, Arcutis, Asana, AsepticMD, Avillion, Bausch Health, Cara, Concert, Dermavant, Edessa Biotech, EPI Health, Fit Bit, Galderma, Genentech/Novartis, Incyte, Janssen, L'Oreal, Leo, Level-Ex, Lilly, LUUM, Oculus, Peloton, Pfizer, Regeneron/Sanofi, Sol-Gel, Trevi, UCB, and Vyne. Dr Taylor serves on the Board of Directors and receives honoraria from CannTec; serves on advisory boards, is a consultant, and/or speaker/faculty education and receives honoraria and/or stock options from AbbVie, Arcutis Biotherapeutics, Inc, Armis Scientific, Beiersdorf, Inc, Biorez, Inc, Cara Therapeutics, EPI Pharma, Evolus, Inc, Galderma Laboratories, L.P., GloGetter, Hugel America, Inc, Janssen, Johnson & Johnson Consumer Products Company, L'Oreal USA, Medscape/WebMD, Piction Health, Scientis U.S., UCB, and Vichy Laboratoires; is a speaker/faculty education with no compensation for Evolus, Inc, and L'Oreal USA; is on the editorial board and reports no compensation for Practical Dermatology, Cutis, and Archives in Dermatologic Research; is an author and receives book royalties from McGraw-Hill; is an investigator and reports no compensation for Concert Pharmaceuticals, Croma-Pharma, Eli Lilly, Pfizer Investigator; and reports a spouse is an employee of and receives a salary from CannTec.